Tempest Therapeutics, Inc. (TPST)

NASDAQ: TPST · IEX Real-Time Price · USD
2.49
+0.34 (15.81%)
At close: Aug 15, 2022 3:59 PM
2.50
+0.01 (0.40%)
After-hours: Aug 15, 2022 6:54 PM EDT
15.81%
Market Cap 25.70M
Revenue (ttm) n/a
Net Income (ttm) -31.44M
Shares Out 10.32M
EPS (ttm) -5.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 73,530
Open 2.11
Previous Close 2.15
Day's Range 2.11 - 2.54
52-Week Range 2.00 - 16.39
Beta n/a
Analysts Buy
Price Target 22.95 (+821.7%)
Earnings Date Aug 10, 2022

About TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was fo... [Read more...]

Industry Biotechnology
Founded 2011
CEO Julia Owens
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TPST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TPST stock is "Buy." The 12-month stock price forecast is 22.95, which is an increase of 821.69% from the latest price.

Price Target
$22.95
(821.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targ...

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets

Tempest to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targ...

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 AS...

SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that combine both targeted and immune-medi...

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targe...

Why Tempest Therapeutics Shares Are Rising

Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading higher by 29.24% at $3.05 after the company announced $15 million of private placement financing.  The $15 million private investment in public...

Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapeutics that combine both targeted and immune...

Tempest Announces Private Placement Financing of $15 Million

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted and ...

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combi...

Tempest Reports Year End 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both tar...

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both tar...

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both tar...

Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

SOUTH SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both t...

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...

Tempest to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combi...

Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights

Closed merger transaction resulting in public listing (TPST)

H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics

H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%.  A strategic portfolio of targeted ther...

What's Going On With Tempest Therapeutics Stock?

Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild ...

TPST Stock: 13 Things to Know About Tempest Therapeutics as Shares Skyrocket Post-Merger

Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as S...

Tempest to Participate in William Blair 2021 Biotech Focus Conference

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combin...

Tempest Announces Appointment of Christine Pellizzari to its Board of Directors

SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that co...

Tempest Closes Merger with Millendo and Completes PIPE Financing

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics...

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.

NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: ht...

MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Mi...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therape...